Hepatitis C in the HIV (Human Immunodeficiency Virus) Atlanta V.A. (Veterans Affairs Medical Center) cohort study (HAVACS): The effect of coinfection on survival

Clinical Infectious Diseases

Volumn 29, Issue 1, 1999, Pages 150-154

  Staples Jr , C T ^a   Rimland, D ^a,b   Dudas, D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS C ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; AGING; ARTICLE; COMORBIDITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0032803881     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520144     Document Type: Article

References (33)

1. 1. Management of hepatitis C. NIH Consens Statement 1997;15:1-41.
2. 2. Hayashi PH, Flynn NH, McCurdy SA, Kuramoto IK, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991;33:177-80.
3. 3. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993;17:117-9.
4. 4. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G, for the Italian Seroconversion Study. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. J Infect Dis 1995;172:1503-8.
5. 5. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996;23:1117-25.
6. 6. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997;175:164-8.
7. 7. Vogt RL, Richmond-Crum S, Diwan A. Hepatitis C virus infection in a human immunodeficiency virus positive cohort in Hawaii. J Infect Dis 1997;176:542.
8. 8. Rich JD, Chin-Hong PV, Busi KA, Mayer KH, Flanigan TP. Hepatitis C and HIV in male prisoners. J AIDS 1997;5:408-9.
9. 9. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-53.
10. 10. Soriano V, Bravo R, Mas A, Garcia-Samaniego J, the Hepatitis-HIV Spanish Study Group. Hepatitis C viremia in HIV-infected patients. AIDS 1996;10:922-3.
11. 11. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 1996;41:1265-72.
12. 12. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5.
13. 13. Roger PM, Saint-Paul MC, Fuzibet JG, Mondain V, Michiels JF, Dellamonica P. Influence of HIV infection on chronic hepatitis C: support for immune-mediated pathogenesis of hepatitis C virus infection [abstract no I-167]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
14. 14. DiMartino V, Rufat P, Martinot M, et al. Detrimental influence of HIV infection on the outcome of chronic hepatitis C: a multivariate analysis [abstract no H-37]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
15. 15. Jenny-Avital ER. Outcome of dual HIV hepatitis C infection [abstract no 96]. In: Abstracts of the 35th annual meeting of the Infectious Diseases Society of America. Clin Infect Dis 1997;25:373.
16. 16. Wright TL, Hollander H, Pu X, Held MJ, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994;20:1152-5.
17. 17. Babudieri S, Cossu PA, Tocco A, et al. Course of patients coinfected with HIV and hepatotropic viruses. Hepatology 1994;20:A255.
18. 18. Dimitrakapoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. Prevalence of hepatitis B and C in HIV positive Greek patients: relationship to survival of AIDS patients [abstract no 513]. In: Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America. Clin Infect Dis 1997;25:450.
19. 19. Rich JD, Dickinson BP, Merriman NA, Czamecki GC, Flanigan TP. Hepatitis C does not impact HIV plasma viral loads in HIV infected women [abstract no 16-019]. In: Abstracts of the 8th International Congress on Infectious Diseases. Boston: International Society for Infectious Diseases, 1998:48.
20. 20. Gupta A, Hoffman-Terry M. Relationship between hepatitis C virus viral load and HIV viral load: a case control study [abstract no I-162]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
21. 21. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998;12:381-8.
22. 22. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
23. 23. Thomas DL, Cannon RO, Shapiro CN, Hook EW, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169:990-5.
24. 24. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997;26(suppl 1):66S-70S.
25. 25. Soriano V, Valencia E, Laguna F, Gonzalez-Lahoz J. High morbidity and mortality associated with non-AIDS defining conditions in HIV-infected patients in Spain. Genitourin Med 1994;70:355-6.
26. 26. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998;177:783-5.
27. 27. Pastor A, Ferreira-Gonzalez A, Fisher L, Garrett CT, Fisher EJ. Hepatitis C virus and HIV viral load in co-infected patients undergoing anti-HIV retroviral therapy [abstract no I-163]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
28. 28. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998;12:116-7.
29. 29. Maus S, Jablonowski H, Klinker H, et al. Success of treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 influenced by CD4 cell count [abstract no I-164]. In:Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
30. 30. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165:723-6.
31. 31. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:585-91.
32. 32. Soriano V, Bravo R, Garcia-Samaniego J, et al. Relapses of chronic hepatitis C in HIV-infected patients who respond to interferon therapy. AIDS 1997;11:400-1.
33. 33. Dupon M, Trimoulet P, Pellegrin I, et al. Serum hepatitis C virus (HCV) RNA levels in patients coinfected with human immunodeficiency virus (HIV) during combination therapy with recombinant interferon-alpha2b (TFNa) and nucleoside analogues [abstract no I-166]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.